Values as of: 2024-11-14
COMMON STOCK | Biotechnology |
Last Closing
USD 0.43Change
0.00 (0.00)%Market Cap
USD 8.61BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Company Website : https://www.sinobiopharm.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| UCBJY | UCB SA ADR |
-2.56 (-2.65%) |
USD 37.20B |
| UCBJF | UCB SA |
N/A |
USD 36.42B |
| ARGNF | argenx SE |
N/A |
USD 35.17B |
| GNMSF | Genmab A/S |
+4.82 (+2.23%) |
USD 14.18B |
| WXIBF | WuXi Biologics |
-0.39 (-17.51%) |
USD 9.23B |
| IVBIY | IVBIY |
N/A |
USD 8.96B |
| ZLDPF | Zealand Pharma A/S |
-1.00 (-0.86%) |
USD 8.69B |
| WXXWY | WuXi Biologics (Cayman) Inc |
-0.19 (-4.74%) |
USD 8.62B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 8.43B |
| AKESF | Akeso, Inc. |
-0.05 (-0.55%) |
USD 8.00B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -31.09% | 39% | F | 30% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -31.09% | 39% | F | 30% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -42.09% | 36% | F | 25% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -42.09% | 36% | F | 25% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -70.95% | 47% | F | 28% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -70.95% | 47% | F | 28% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -23.69% | 21% | F | 10% | F | ||
| Dividend Return | -24.40% | 21% | F | 10% | F | ||
| Total Return | -0.71% | 17% | F | N/A | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 22.06% | 94% | A | 84% | B | ||
| Risk Adjusted Return | -110.60% | 8% | B- | 3% | F | ||
| Market Capitalization | 8.61B | 97% | N/A | 90% | A- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
